Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects

Targeting host factors exploited by multiple viruses could offer broad-spectrum solutions for pandemic preparedness. Seventeen candidates targeting diverse functions emerged in a screen of 4,413 compounds for SARS-CoV-2 inhibitors. We demonstrated that lapatinib and other approved inhibitors of the ErbB family receptor tyrosine kinases suppress replication of SARS-CoV-2, Venezuelan equine encephalitis virus (VEEV), and other emerging viruses with a high barrier to resistance. Lapatinib suppressed SARS-CoV-2 entry and later stages of the viral life cycle and showed synergistic effect with the direct-acting antiviral nirmatrelvir. We discovered that ErbB1, 2 and 4 bind SARS-CoV-2 S1 protein and regulate viral and ACE2 internalization, and they are required for VEEV infection. In human lung organoids, lapatinib protected from SARS-CoV-2-induced activation of ErbB-regulated pathways implicated in non-infectious lung injury, pro-inflammatory cytokine production, and epithelial barrier injury. Lapatinib suppressed VEEV replication, cytokine production and disruption of the blood-brain barrier integrity in microfluidic-based human neurovascular units, and reduced mortality in a lethal infection murine model. We validated lapatinib-mediated inhibition of ErbB activity as an important mechanism of antiviral action. These findings reveal regulation of viral replication, inflammation, and tissue injury via ErbBs and establish a proof-of-principle for a repurposed, ErbB-targeted approach to combat emerging viruses.

[1]  Seo Jung Hong,et al.  Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir , 2022, bioRxiv.

[2]  B. Pinsky,et al.  Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies , 2022, Antiviral Research.

[3]  J. Caramelo,et al.  ACE2 internalization induced by a SARS-CoV-2 recombinant protein is modulated by angiotensin II type 1 and bradykinin 2 receptors , 2022, Life Sciences.

[4]  B. Kraemer,et al.  A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease , 2021, PloS one.

[5]  E. Lazartigues,et al.  Angiotensin Type 1 Receptor-Dependent Internalization of SARS-CoV-2 by Angiotensin-Converting Enzyme 2 , 2021, Hypertension.

[6]  J. Dye,et al.  BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals. , 2020, Antiviral research.

[7]  L. Martínez-Sobrido,et al.  Generation of Recombinant SARS‐CoV‐2 Using a Bacterial Artificial Chromosome , 2020, Current protocols in microbiology.

[8]  Arthur S Slutsky,et al.  Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.

[9]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[10]  S. Einav,et al.  Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19 , 2020, ACS infectious diseases.

[11]  Yuan Yu,et al.  HMGB1/PI3K/Akt/mTOR Signaling Participates in the Pathological Process of Acute Lung Injury by Regulating the Maturation and Function of Dendritic Cells , 2020, Frontiers in Immunology.

[12]  D. Matthews,et al.  Neuropilin-1 is a host factor for SARS-CoV-2 infection , 2020, Science.

[13]  P. Spagnolo,et al.  Pulmonary fibrosis secondary to COVID-19: a call to arms? , 2020, The Lancet Respiratory Medicine.

[14]  P. Maes,et al.  STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters , 2020, bioRxiv.

[15]  Qi Zhou,et al.  The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS , 2020, Aging.

[16]  J. Penninger,et al.  Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells , 2020, Emerging microbes & infections.

[17]  Yao-lan Li,et al.  Tandem mass tag-based quantitative proteomic analysis of lycorine treatment in highly pathogenic avian influenza H5N1 virus infection , 2019, PeerJ.

[18]  M. Fatima,et al.  Antiviral evaluation of an Hsp90 inhibitor, gedunin, against dengue virus , 2017 .

[19]  D. Moyes,et al.  The Role of ErbB Receptors in Infection , 2017, Trends in Microbiology.

[20]  M. Frieman,et al.  Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection , 2017, Journal of Virology.

[21]  J. Dye,et al.  Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects , 2017, The Journal of clinical investigation.

[22]  E. Evron,et al.  Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature , 2017, Journal of chemotherapy.

[23]  Jun Chen,et al.  Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth , 2016, Molecular Cancer Therapeutics.

[24]  E. Perez,et al.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Lei Wan,et al.  SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 MAPK/STAT3 pathway , 2016, Scientific Reports.

[26]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[27]  S. Akhtar,et al.  Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor , 2015, PloS one.

[28]  A. Luster,et al.  The chemokine system in innate immunity. , 2015, Cold Spring Harbor perspectives in biology.

[29]  G. Olinger,et al.  Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis , 2014, Antimicrobial Agents and Chemotherapy.

[30]  Isabelle Marois,et al.  Inhibition of Influenza Virus Replication by Targeting Broad Host Cell Pathways , 2014, PloS one.

[31]  M. Denison,et al.  Coronaviruses Induce Entry-Independent, Continuous Macropinocytosis , 2014, mBio.

[32]  S. Ōmura,et al.  Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression , 2014, The Journal of Antibiotics.

[33]  A. Watson,et al.  Stable, High-Level Expression of Reporter Proteins from Improved Alphavirus Expression Vectors To Track Replication and Dissemination during Encephalitic and Arthritogenic Disease , 2013, Journal of Virology.

[34]  M. Teixeira,et al.  ACE2, angiotensin‐(1‐7) and Mas receptor axis in inflammation and fibrosis , 2013, British journal of pharmacology.

[35]  D. Gustafson,et al.  Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[36]  Y. Jacob,et al.  Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly , 2012, PLoS pathogens.

[37]  H. Schätzl,et al.  Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain , 2012, Journal of Virology.

[38]  A. Pandiella,et al.  Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications , 2012, International journal of cancer.

[39]  S. Hurvitz,et al.  Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. , 2012, Breast cancer.

[40]  J. Frydman,et al.  Broad action of Hsp90 as a host chaperone required for viral replication. , 2012, Biochimica et biophysica acta.

[41]  Lianfeng Zhang,et al.  Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication , 2011, Virology Journal.

[42]  R. Johnston,et al.  The Role of the Blood-Brain Barrier during Venezuelan Equine Encephalitis Virus Infection , 2011, Journal of Virology.

[43]  Bing-he Xu,et al.  Chinese Anti鄄 Cancer a Ssociation , 2022 .

[44]  H. Hricak,et al.  CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. , 2011, Radiology.

[45]  M. Desilvio,et al.  A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer , 2010, Oncology.

[46]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[47]  E. Martin,et al.  Rapid-Onset Acute Respiratory Distress Syndrome (ARDS) in a Patient Undergoing Metastatic Liver Resection: A Case Report and Review of the Literature , 2010, Anesthesiology research and practice.

[48]  Paul D. Smith,et al.  AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer , 2010, Clinical Cancer Research.

[49]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[50]  G. Supinski,et al.  Calpain activation contributes to endotoxin-induced diaphragmatic dysfunction. , 2010, American journal of respiratory cell and molecular biology.

[51]  T. Peng,et al.  Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. , 2009, Cardiovascular research.

[52]  M. Arbushites,et al.  Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  Ron Bose,et al.  Mechanism of activation and inhibition of the HER4/ErbB4 kinase. , 2008, Structure.

[54]  T. Hyypiä,et al.  Calpain 1 and 2 Are Required for RNA Replication of Echovirus 1 , 2007, Journal of Virology.

[55]  Takeshi Fukuda,et al.  Gefitinib prevents bleomycin-induced lung fibrosis in mice. , 2006, American journal of respiratory and critical care medicine.

[56]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  K. Hertogs,et al.  Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus , 2005, Journal of Virological Methods.

[58]  P. Xiao,et al.  Identification of natural compounds with antiviral activities against SARS-associated coronavirus , 2005, Antiviral Research.

[59]  E. Leffel,et al.  Marburg and Ebola viruses as aerosol threats. , 2004, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[60]  T. Mizutani,et al.  Phosphorylation of p38 MAPK and its downstream targets in SARS coronavirus-infected cells , 2004, Biochemical and Biophysical Research Communications.

[61]  F. Achike,et al.  Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. , 2002, Acta pharmacologica Sinica.

[62]  R. DeBiasi,et al.  Calpain Inhibition Protects against Virus-Induced Apoptotic Myocardial Injury , 2001, Journal of Virology.

[63]  J. Whitsett,et al.  Reversal of lung lesions in transgenic transforming growth factor alpha mice by expression of mutant epidermal growth factor receptor. , 1996, American journal of respiratory cell and molecular biology.

[64]  M. Prichard,et al.  Analysis of combinations of antiviral drugs and design of effective multidrug therapies. , 1996, Antiviral therapy.

[65]  S. Keyse,et al.  Tyrosine kinase inhibition: an approach to drug development. , 1995, Human & experimental toxicology.

[66]  S. Yamazaki,et al.  The antiviral effect of phorbol ester and calcium ionophore A23187 is not mediated by interferons. , 1991, Journal of interferon research.

[67]  N. Katunuma,et al.  Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. , 1990, Journal of enzyme inhibition.

[68]  A. Vlietinck,et al.  Plant Antiviral Agents , 1983, Planta medica.

[69]  DifcoTM HycheckTM,et al.  The package insert. , 1969, JAMA.